Latest Ratios: P/E Ratio -60.7x · EV/EBITDA 125.5x · ROE -12.4%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.5B | $2.1B | $2.0B | $1.1B | $4.1B | $6.0B | $3.0B | $1.2B | $704M | $665M |
| Enterprise Value | $2.3B | $1.8B | $2.3B | $2.3B | $1.5B | $4.4B | $6.0B | $3.0B | $1.3B | $796M | $758M |
| P/E Ratio → | -60.71 | — | — | — | — | — | 1443.43 | 378.40 | 437.85 | — | — |
| P/S Ratio | 2.49 | 2.07 | 3.16 | 3.43 | 2.25 | 8.45 | 13.54 | 7.41 | 4.17 | 2.93 | 2.72 |
| P/B Ratio | 2.34 | 1.80 | 2.31 | 2.16 | 1.15 | 3.69 | 8.67 | 5.97 | 3.60 | 3.42 | 3.56 |
| P/FCF | — | — | — | — | — | — | — | 907.41 | 37.89 | 161.89 | 47.67 |
| P/OCF | 374.94 | 288.04 | 297.21 | — | — | — | 4122.60 | 129.69 | 25.78 | 39.02 | 30.94 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.50 | 3.52 | 3.89 | 2.93 | 9.06 | 13.52 | 7.32 | 4.54 | 3.31 | 3.11 |
| EV / EBITDA | 125.52 | 1042.48 | — | — | — | — | 276.52 | 69.10 | 39.57 | 31.24 | 29.41 |
| EV / EBIT | — | — | — | — | — | — | — | 406.44 | 125.22 | 201.09 | 351.82 |
| EV / FCF | — | — | — | — | — | — | — | 895.39 | 41.25 | 183.19 | 54.38 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 38.8% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 45.2% |
| Operating Margin | -9.1% | -9.1% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | 3.6% | 1.2% | 1.1% |
| Net Profit Margin | -14.9% | -14.9% | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% | 2.0% | 1.0% | -0.2% | -2.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.4% | -12.4% | -8.5% | -9.1% | -13.7% | -0.9% | 0.7% | 1.9% | 1.0% | -0.2% | -2.9% |
| ROA | -7.2% | -7.2% | -4.7% | -5.1% | -8.0% | -0.6% | 0.5% | 1.3% | 0.6% | -0.1% | -1.7% |
| ROIC | -4.3% | -4.3% | -5.9% | -6.3% | -8.6% | -8.5% | -1.8% | 2.2% | 2.1% | 0.8% | 0.7% |
| ROCE | -5.1% | -5.1% | -6.3% | -6.7% | -9.2% | -8.8% | -1.8% | 2.4% | 2.7% | 1.0% | 0.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.56 | 0.56 | 0.67 | 0.65 | 0.61 | 0.55 | 0.31 | 0.26 | 0.35 | 0.51 | 0.57 |
| Debt / EBITDA | 270.65 | 270.65 | — | — | — | — | 10.04 | 3.07 | 3.53 | 4.14 | 4.12 |
| Net Debt / Equity | — | 0.37 | 0.26 | 0.29 | 0.35 | 0.27 | -0.02 | -0.08 | 0.32 | 0.45 | 0.50 |
| Net Debt / EBITDA | 179.17 | 179.17 | — | — | — | — | -0.48 | -0.93 | 3.23 | 3.63 | 3.63 |
| Debt / FCF | — | — | — | — | — | — | — | -12.02 | 3.36 | 21.30 | 6.72 |
| Interest Coverage | -28.38 | -28.38 | -11.19 | -13.06 | -20.02 | -0.83 | -1.00 | 1.98 | 1.61 | 0.71 | 0.22 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.26 | 4.26 | 1.98 | 6.20 | 6.73 | 7.81 | 6.13 | 4.55 | 1.70 | 2.42 | 1.32 |
| Quick Ratio | 3.94 | 3.94 | 1.89 | 5.95 | 6.46 | 7.54 | 5.73 | 4.32 | 1.56 | 2.21 | 1.21 |
| Cash Ratio | 1.81 | 1.81 | 1.28 | 4.31 | 4.87 | 5.91 | 4.05 | 2.71 | 0.16 | 0.37 | 0.21 |
| Asset Turnover | — | 0.53 | 0.40 | 0.35 | 0.29 | 0.26 | 0.45 | 0.58 | 0.55 | 0.70 | 0.72 |
| Inventory Turnover | 15.57 | 15.57 | 13.85 | 14.37 | 13.26 | 12.71 | 8.76 | 14.72 | 17.28 | 18.50 | 21.38 |
| Days Sales Outstanding | — | 79.91 | 83.18 | 80.98 | 85.72 | 84.50 | 87.74 | 85.03 | 101.45 | 91.80 | 83.01 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.1% | 0.3% | 0.2% | — | — |
| FCF Yield | — | — | — | — | — | — | — | 0.1% | 2.6% | 0.6% | 2.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4.3% | 0.0% | 8.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4.3% | 0.0% | 8.3% |
| Shares Outstanding | — | $128M | $127M | $126M | $124M | $120M | $112M | $104M | $92M | $79M | $78M |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEO stock.
NeoGenomics, Inc.'s current P/E ratio is -60.7x. The historical average is 29.9x.
NeoGenomics, Inc.'s current EV/EBITDA is 125.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.9x.
NeoGenomics, Inc.'s return on equity (ROE) is -12.4%. The historical average is -39.4%.
Based on historical data, NeoGenomics, Inc. is trading at a P/E of -60.7x. Compare with industry peers and growth rates for a complete picture.
NeoGenomics, Inc. has 38.8% gross margin and -9.1% operating margin.
NeoGenomics, Inc.'s Debt/EBITDA ratio is 270.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Persistent operating losses at scale
Metrics are mathematically derived from official filings.
Trailing Losses Versus Forward Earnings Gap
Based on reported figures, NEO trades at a negative trailing P/E of -4.01 but a forward P/E of 83.45 and forward EV/EBITDA of 7.38, a divergence that signals the market is pricing a recovery in earnings rather than rewarding current profitability.
The gap between trailing and forward multiples reflects that recent quarters have produced operating losses, so trailing metrics are not meaningful for pricing. The forward P/E of 83.45 implies investors are assuming substantial earnings expansion, which may be optimistic given that operating margin has only recently moved from -26.3% toward -3.8%. The P/B of 0.52 and P/S of 0.59 suggest the stock is priced below book and below sales, a level that may reflect skepticism about whether the goodwill-heavy asset base generates adequate returns.
Gross Margin Recovery Outpaces Operating Breakeven
As reported in financial statements, NEO's gross margin recovered from 39.8% in 2025Q4 to 46.2% in 2026Q3, while operating margin only improved to -3.8%, indicating that operating expenses still absorb nearly all incremental gross profit.
The improvement in gross margin is encouraging, but the persistent negative operating margin shows that SG&A and R&D growth has kept pace with gross profit gains. Net margin of -3.6% in 2026Q3 is close to operating margin, which suggests interest and other items are not the main drag, so the core issue is cost structure. Gross margin is the cleanest indicator of pricing and test mix trends here, while operating margin better reflects true earning power at this stage.
Negative Returns Narrowing but Not Yet Positive
Based on NEO's reported figures, ROIC moved from -3.2% in 2025Q2 to -0.5% in 2026Q3 and ROE from -5.2% to -1.0%, a trajectory toward breakeven returns that remains unproven over the ten-quarter window.
Both ROIC and ROE are improving, yet they remain negative, so the company is not yet earning its cost of capital on the large asset base. Goodwill of $524.0M inflates invested capital, which mechanically depresses returns and makes the improvement partly a function of acquisition accounting. Investors should monitor whether operating income turns durably positive, since returns on a goodwill-heavy base can only compound once earnings clear the capital charge.
Leverage Easing With Thin Interest Coverage
According to reported figures, NEO's debt-to-equity fell from 0.66 in 2024Q2 to 0.56 in 2026Q3 and total debt dropped to $449.1M, but interest coverage swings between positive and deeply negative values make debt service comfort difficult to assess.
The deleveraging trend is constructive, with debt reduced by roughly $157M over the period while equity remained above $800M. However, interest coverage is erratic because EBIT has been negative in most quarters, so the metric reflects operating losses rather than a stable debt service capacity. Debt-to-EBITDA values of 54 to 90 in recent quarters indicate that EBITDA is too small to support the debt load on a cash basis, which warrants further investigation into refinancing terms.
Strong Current Ratio Masks Shrinking Cash
Based on reported figures, NEO's current ratio of 3.53 in 2026Q3 appears comfortable, yet cash declined to $139.3M from $346.2M a year earlier, narrowing the actual liquidity buffer against $449.1M of total debt.
A current ratio above 3.5 looks robust, but it is driven largely by receivables and inventory rather than cash, and the quick ratio of 3.31 is only modestly lower, suggesting most current assets are not inventory-dependent. The sharp reduction in cash is the more relevant signal, since it shows that operating and investing outflows have consumed liquidity. Under a severe stress scenario, the position would depend on collecting receivables and sustaining cash generation, which the mixed cash flow record does not guarantee.
Misapplied Ratio: EV/EBITDA Distorted by Thin Earnings
The EV/EBITDA ratio is most commonly misapplied here, as NEO's reported EV/EBITDA of 427.14 on trailing figures obscures the earnings base, and forward multiples of 7.38 depend heavily on recovery assumptions investors should monitor.
Trailing EV/EBITDA becomes meaningless when EBITDA is near zero, so the reported 427 figure reflects a tiny denominator rather than a valuation level. Price-to-sales or forward EV/EBITDA, adjusted for stock-based compensation and acquisition amortization, would better convey what the market is paying for revenue and recovered earnings. Because roughly $16M to $18M of quarterly D&A and SBC are excluded from EBITDA add-backs, investors should test whether the forward multiple holds once these costs are treated as real expenses.